Literature DB >> 9525431

Virologic, immunologic, and clinical parameters in the incidence and progression of anal squamous intraepithelial lesions in HIV-positive and HIV-negative homosexual men.

J M Palefsky1, E A Holly, C J Hogeboom, M L Ralston, M M DaCosta, R Botts, J M Berry, N Jay, T M Darragh.   

Abstract

Anal cancer may be preceded by anal squamous intraepithelial lesions (ASIL), but the natural history of ASIL is poorly understood. In this report, we characterize the 2-year incidence and progression of low-grade SIL (LSIL) and high-grade SIL (HSIL) in a cohort study in 346 HIV-positive and 262 HIV-negative homosexual or bisexual men. Subjects were studied at defined intervals using anal cytology, anoscopy with biopsy of visible lesions, human papillomavirus (HPV) testing, HIV serostatus, CD4 level, and data on medical history and lifestyle. The incidence of HSIL within 2 years was 20% in HIV-positive men and 8% in HIV-negative men who were normal at baseline. In total, 62% of HIV-positive and 36% of HIV-negative men with LSIL at baseline progressed to HSIL. The relative risk (RR) for anal disease progression in HIV-positive men was 2.4 (95% confidence interval [CI], 1.8-3.2) when compared with HIV-negative men. The RR increased to 3.1 (95% CI, 2.3-4.1) in HIV-positive men with CD4 counts <200/mm3. Infection with multiple HPV types was a risk factor for anal disease progression in both HIV-positive (RR = 2.0; 95% CI, 1.0-4.1) and HIV-negative (RR = 5.1; 95% CI, 2.3-11) men. The incidence of anal HSIL and progression of LSIL to HSIL within 2 years of follow-up is high in HIV-positive homosexual or bisexual men and to a lesser extent, in HIV-negative men. Men with the above risk factors may be at increased risk of developing anal cancer.

Entities:  

Mesh:

Year:  1998        PMID: 9525431     DOI: 10.1097/00042560-199804010-00004

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr Hum Retrovirol        ISSN: 1077-9450


  59 in total

Review 1.  Multidisciplinary Approach to the Management and Treatment of Anal Dysplasia.

Authors:  Jeffrey Douaiher; Sean J Langenfeld
Journal:  Clin Colon Rectal Surg       Date:  2018-11-02

2.  Non-AIDS-Defining Cancers and HIV Infection.

Authors:  Soon Thye Lim; Alexandra M Levine
Journal:  Curr Infect Dis Rep       Date:  2005-05       Impact factor: 3.725

3.  Human papillomavirus, condylomata acuminata, and anal neoplasia.

Authors:  George J Chang; Mark L Welton
Journal:  Clin Colon Rectal Surg       Date:  2004-11

4.  Description of a pilot anal pap smear screening program among individuals attending a Veteran's Affairs HIV clinic.

Authors:  Isabella Rosa-Cunha; Vincent A Degennaro; Rene Hartmann; Clara Milikowski; Andres Irizarry; Brenda Heitman; Orlando Gómez-Marín; Gordon M Dickinson
Journal:  AIDS Patient Care STDS       Date:  2011-03-02       Impact factor: 5.078

5.  The role of Human Papilloma Virus (HPV) vaccination in the prevention of anal cancer in individuals with Human Immunodeficiency Virus-1 (HIV-1) infection.

Authors:  Luis F Barroso
Journal:  Ther Adv Vaccines       Date:  2013-07

6.  Epidermoid carcinoma of the anal canal.

Authors:  Bruce W Robb; Matthew G Mutch
Journal:  Clin Colon Rectal Surg       Date:  2006-05

7.  Efficacy of trichloroacetic acid in the treatment of anal intraepithelial neoplasia in HIV-positive and HIV-negative men who have sex with men.

Authors:  Jasmeet Chadha Singh; Victoria Kuohung; Joel M Palefsky
Journal:  J Acquir Immune Defic Syndr       Date:  2009-12-01       Impact factor: 3.731

8.  Treatment of high-grade anal dysplasia in high-risk patients: outcome at an urban community health centre.

Authors:  S A Assoumou; L A Panther; Y Feng; R S Gelman; D K Fugelso; K H Mayer
Journal:  Int J STD AIDS       Date:  2013-05-06       Impact factor: 1.359

9.  Risk factors for anal human papillomavirus infection type 16 among HIV-positive men who have sex with men in San Francisco.

Authors:  Alexandra L Hernandez; Jimmy T Efird; Elizabeth A Holly; J Michael Berry; Naomi Jay; Joel M Palefsky
Journal:  J Acquir Immune Defic Syndr       Date:  2013-08-01       Impact factor: 3.731

10.  Anal dysplasia screening: an evidence-based analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2007-06-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.